Strategies to modulate Reelin therapeutically show that using monoclonal antibodies to deplete Reelin peripherally can reduce neuroinflammation without affecting the function of the central nervous system [37], while improving Reelin signaling has demonstrated neuroprotective effects in AD models and may reduce tau pathology, as demonstrated by a protective RELN variant in a human AD-resilient case [22]. This evidence concerns the gene MAPT and Alzheimer disease.